Kunming Longjin Pharmaceutical (002750.SZ) has received the registration certificate for orally disintegrating sildenafil citrate tablets.

Kunming Longjin Pharmaceutical (002750.SZ) announced that its holding subsidiary Yunnan Longjin Kangyou Biomedical Pharmaceuticals Co., Ltd. (referred to as "Longjin Kangyou") recently received the "Drug Registration Certificate" (Certificate No.: 2024S02682) for the sildenafil citrate orally disintegrating tablets approved by the National Medical Products Administration. Sildenafil citrate is the world's first approved type 5 phosphodiesterase selective inhibitor for the treatment of erectile dysfunction, with advantages such as rapid onset of action and definite efficacy, making it the most widely used first-line treatment for erectile dysfunction in clinical practice in China.